Herpetic Eye Disease Following the SARS-CoV-2 Vaccinations

Cohen, Shai; Olshaker, Hagar; Fischer, Naomi; Vishnevskia‐Dai, Vicktoria; Hagin, David; Rosenblatt, Amir; Zur, Dinah; Habot‐Wilner, Zohar

doi:10.1080/09273948.2022.2103831

Cited by 13 publications

(7 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 In addition to case reports of HZO and HSO after vaccination with BNT162b2 and mRNA-1273 vaccines, 2 case series (Rallis et al and Cohen et al) have reported HZO and HSO cases in 10 and 5 patients, respectively. 10,29 As advancing age is a risk factor for HZO and HSO reactivation, most of the patients in this study were in their sixth and eighth decades. Almost all patients with HSO and HZO reactivation in the above mentioned case series were also in similar age groups.…”

Section: Discussionmentioning

confidence: 94%

Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis

Singh

Parmar

Ichhpujani

et al. 2023

Cornea

View full text Add to dashboard Cite

Purpose:The aim of this study was to evaluate the cases of herpes simplex and zoster ophthalmicus after SARS-CoV-2 vaccination and assess the clinical presentations in patients.Methods:A retrospective analysis of cases reported to the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS) between December 11, 2020, and July 1, 2022. Patients diagnosed with herpes simplex ophthalmicus (HSO) and herpes zoster ophthalmicus (HZO) after vaccination with BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and Ad26.COV2.S (Janssen) were included in the study. We performed a descriptive analysis of patient demographics, history, and ophthalmic and systemic clinical presentations. The correlations between vaccine type and continuous variables were assessed by the one-way analysis of variance test. In addition, we used the Pearson χ2 test to assess the association between 3 vaccines and categorical variables. A post hoc analysis was performed between HSO and HZO onset intervals after vaccination, dose, and vaccine type. The 30-day risk analysis was also performed for HSO and HZO onset postvaccination using the reverse Kaplan–Meier analysis.Results:A total of 1180 cases of HZO (983, 83.30%) and HSO (180, 15.25%) were reported. The mean age of patients with HZO and HSO was 59.02 ± 19.05 and 52.68 ± 17.83 years, respectively. Most of the cases of HZO (795, 80.87%) and HSO (131, 72.78%) were reported in patients who received BNT162b2. In the cohort, 63.28% and 65.56% diagnosed with HZO and HSO were women. About one third of HZO (36.52%) and HSO (35.56%) cases were reported after the first dose. More than half of the cases of HZO (61.34%) and HSO (64.45%) were reported within the first 2 weeks after vaccination. The estimated crude reporting rate (per million doses) in the United States was 0.25, 0.22, and 0.47 for BNT162b2, mRNA-1273, and Ad26.COV2.S, respectively. The onset interval for HZO was significantly shorter in patients who received BNT162b2 (20.51 ± 56.20 days, P = 0.030) compared with patients who received mRNA-1273 (36.56 ± 108.67 days) and Ad26.COV2.S (39.66 ± 60.15 days) vaccines. The 30-day risk analysis showed a significantly higher risk of HZO after BNT162b2 than the other 2 vaccines (P = 0.011).Conclusions:The low crude reporting rate suggests that HZO and HSO after SARS-CoV-2 vaccination occur rarely. This study provides insights into the possible temporal association between reported HSO and HZO after SARS-CoV-2 vaccines; however, further investigations are required to delineate the possible underlying immunological mechanisms.

show abstract

Section: Discussionmentioning

confidence: 94%

Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis

Singh

Parmar

Ichhpujani

et al. 2023

Cornea

View full text Add to dashboard Cite

show abstract

“…A total of 65 studies were both qualitatively and quantitatively analyzed ( Table 1 ) [ 1 , 5 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 ,…”

Section: Resultsmentioning

confidence: 99%

The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review

et al. 2022

View full text Add to dashboard Cite

Numerous complications following COVID-19 vaccination has been reported in the literature, with an increasing body of evidence reporting vaccination-associated uveitis (VAU). In this systematic review, we searched six electronic databases for articles reporting the occurrence of VAU following COVID-19 vaccination. Data were synthesized with emphasis on patients’ characteristics [age, gender], vaccination characteristics [type, dose], and outcome findings [type, nature, laterality, course, location, onset, underlying cause, and associated findings]. Data are presented as numbers (percentages) for categorical data and as mean (standard deviation) for continuous data. Sixty-five studies were finally included [43 case reports, 16 case series, four cohort, one cross-sectional, and one registry-based study]. VAU occurred in 1526 cases, most commonly in females (68.93%) and middle-aged individuals (41–50 years: 19.71%), following the first dose (49.35%) of vaccination, especially in those who received Pfizer (77.90%). VAU occurred acutely (71.77%) as an inflammatory reaction (88.29%) in unilateral eyes (77.69%), particularly in the anterior portion of the uvea (54.13%). Importantly, most cases had a new onset (69.92%) while only a limited portion of cases had a reactivation of previous uveitis condition. In conclusion, although rare, uveitis following COVID-19 vaccination should be considered in new-onset and recurrent cases presenting with either acute or chronic events.

show abstract

“…It has also been reported that higher rates of flare of these conditions were seen in individuals with higher levels of disease activity and a shorter periods of disease quiescence prior to vaccination. 27 …”

Section: Discussionmentioning

confidence: 99%

“…10 Recent reports have also suggested that vaccines can cause epigenetic changes which affect the immune system’s reactivity, causing a period of vaccine induced immune suppression limiting the body’s ability to keep previously latent infections under control. 27 …”

Section: Discussionmentioning

confidence: 99%